«This is the first study conducted on
the diabetic mouse model that supports the LYP gain - of - function hypothesis,» says Dr. Kissler.
«Novel «smart» insulin automatically adjusts blood sugar in
diabetic mouse model.»
«By decreasing ROS levels within a chronic wound in
a diabetic mouse model, my lab was able to normalize conditions and heal the wound,» Martins - Green said.
In fact, the speed and kinetics of touching down to safe blood glucose levels are identical in
diabetic mouse models treated with Ins - PBA - F and in healthy mice whose blood sugar is regulated by their own insulin.
Not exact matches
One of the most popular
models is the immunodeficient nonobese
diabetic severe combined immunodeficiency (NOD scid) gamma (NSG) transgenic
mouse line, which can be endowed with a humanized immune system using CD34 + hematopoietic stem cells.
The group also tested low - dose topical application of growth factors on
diabetic mice, which are a common
model for impaired wound healing.
To rule out that the induction observed was due to other
diabetic - associated alterations in the pancreas, we performed a control experiment in which we injected Tg - hIAPP
mice with pancreas homogenate from a
diabetic model not associated with IAPP aggregation.
The results demonstrated that this new molecule was safe and effective, causing significant improvement in
mouse models of both acute uveitis and chronic
diabetic inflammation, with no apparent side - effects.
Because PD - L1 / programmed cell death (PD - 1) deficiency accelerates development of diabetes in
mouse models, Nasr et al. hypothesized that a defect in the PD - L1 / PD - 1 pathway may underpin the hyperglycemia observed in the nonobese
diabetic (NOD)
mouse model.
«Our plan is to apply such materials to
diabetic wounds in
mouse models in order to evaluate their efficacy.
Models of obesity - induced type 2 diabetes include the KK
mouse and the Zucker
diabetic fatty (ZDF) ratANCHOR ANCHOR.
The nonobese
diabetic (NOD)
mouse is a common
model used for studying treatments for diabetes.
The Joslin researchers then transplanted these modified human
diabetic cells into wounds in
mice models of diabetes that also had suppressed immune systems so that they didn't reject human cells.